Syngene International Quarterly Results for Trading Insights
In Mar 2026, Syngene International (SYNGENE) reported revenue ₹1,059 Cr and net profit ₹148 Cr — revenue +2.1% YoY. For annual financials, live price and key ratios, visit Syngene International share price chart.
SYNGENE Quarterly Results — Revenue, Profit & EPS Highlights
Syngene International latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with Syngene International value estimation to assess whether the stock is under or overvalued.
- Revenue of ₹1,059 Cr in Mar 2026 (+14.4% vs Sept 2025, +2.1% vs Mar 2025)
- Net Profit of ₹148 Cr in Mar 2026 (+120.9% vs Sept 2025, -19.1% vs Mar 2025)
- EBITDA of ₹320 Cr in Mar 2026 (+48.8% vs Sept 2025)
- Operating Margin of 29.0% in Mar 2026 (+7.0pp vs Sept 2025)
- Earnings Per Share of ₹3.68 in Mar 2026 (+120.4% vs Sept 2025)
Syngene International Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SYNGENE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,059 | 926 | 1,037 | 892 | 933 | 14.4% | 2.1% |
| Net Profit (₹ Cr) | 148 | 67 | 183 | 87 | 15 | - | - |
| EBITDA (₹ Cr) | 320 | 215 | 363 | 224 | 154 | - | - |
| EPS (₹) | 3.68 | 1.67 | 4.56 | 2.16 | 0.37 | - | - |
| Operating Margin (%) | 29.0% | 22.0% | 34.0% | 24.0% | 15.0% | - | - |
SYNGENE Share Price Trend — 1-Year Movement Across Quarterly Results
Syngene International 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore SYNGENE share price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SYNGENE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Syngene International latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1799.2 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 159.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6667.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 235.5 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4410.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 383.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1401.0 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.9 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1303.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores